Sweden's Sedana Medical Q3 sales rise as growth returns

Overview

• Sweden medtech firm's Q3 net sales rose 7% yr/yr as sales growth returned

• Company posted Q3 net loss as investments in sales force increased expenses

• FDA review of US drug application under way, with decision expected April 2027

Outlook

• Sedana Medical expects to meet its financial guidance for the full year

• Company is focused on accelerating commercial execution in core markets in the final quarter

• FDA review of US New Drug Application ongoing, with PDUFA decision date set for April 16, 2027

Result Drivers

• COMMERCIAL EXECUTION - Co said sharper focus on high-potential accounts and increased sales force investments contributed to sales growth in Q3

• MARKET CONDITIONS - Co cited fewer ICU admissions with severe acute respiratory infections in Germany as a factor in sales decline, but noted improvement in Q3

• CONTRACT MANUFACTURING MIX - Co said lower gross margin in Q3 was due to higher share of contract manufacturing sales and absence of prior one-time margin effect

Company press release:

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Reuters Recommended Reads

• Oct 21 - Sweden's Getinge Q3 organic sales rise 2.1%

• Oct 21 - Sweden's AddLife beats Q3 net sales expectations

• Oct 21 - Medical gear maker Getinge beats Q3 profit estimates on pricing, product mix

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)